STOCK TITAN
  1. Home
  2. News
  3. VTVT

vTv Therapeutics Inc - VTVT STOCK NEWS

Welcome to our dedicated news page for vTv Therapeutics (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on vTv Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect vTv Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of vTv Therapeutics's position in the market.

News
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Rhea-AI Summary
Cantex Pharmaceuticals, Inc. announces CEO Stephen Marcus, M.D., to present clinical updates on azeliragon in Phase 2 trials for glioblastoma at the 5th Annual Glioblastoma Drug Development Summit. Azeliragon received FDA Orphan Drug Designation for glioblastoma, providing marketing exclusivity and other benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
News
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Rhea-AI Summary
vTv Therapeutics Inc. reported financial results for Q4 and full year 2023, with a cash position of $9.4 million as of December 31, 2023. The company completed a $51 million private placement for Phase 3 trial of cadisegliatin for type 1 diabetes. Recent milestones include the submission of the study protocol to the FDA and upcoming Phase 2 study in type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
earnings
-
News
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
Rhea-AI Summary
vTv Therapeutics Inc. announces the submission of the study protocol to the FDA for its Phase 3 trial evaluating cadisegliatin as an adjunctive therapy to insulin for type 1 diabetes. The trial aims to enroll 150 patients across 20 sites in the US, with the primary endpoint being the comparison of hypoglycemic events between cadisegliatin-treated and placebo groups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.35%
Tags
clinical trial
News
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
vTv Therapeutics Inc. announces participation in TD Cowen 44th Annual Healthcare Conference to present on cadisegliatin as adjunctive therapy for type 1 diabetes. The presentation is scheduled for March 5, 2024, at 9:50 AM ET, with a live webcast available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
conferences
-
News
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Rhea-AI Summary
vTv Therapeutics Inc. announces closing of a private placement to fund the first Phase 3 study of cadisegliatin for the treatment of type 1 diabetes. The company raised $51 million through the private placement, reducing its Board of Directors and bringing in new high-quality investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.88%
Tags
none
-
News
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
Rhea-AI Summary
Cantex Pharmaceuticals, Inc. announced that CEO Stephen Marcus will participate in the BIO CEO & Investor Conference in New York City. The company is focused on developing therapies for cancer and other medical conditions. Cantex is developing azeliragon, an inhibitor of RAGE, with ongoing Phase 2 trials in various cancers and a Phase 3 trial in pneumonia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
conferences
News
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
Rhea-AI Summary
vTv Therapeutics Inc. (VTVT) reports Q3 2023 financial results and corporate developments, highlighting the appointment of Dr. Thomas Strack as Chief Medical Officer and a common stock repurchase agreement with Reneo Pharmaceuticals. With a cash position of $8.2 million, R&D expenses of $2.8 million, and a net loss of $6.7 million, the company anticipates 2024 to be transformational.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.84%
Tags
earnings
-
News
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
Rhea-AI Summary
vTv Therapeutics Inc. (Nasdaq: VTVT) announced that its CFO, CSO, and CMO will present at the Stifel 2023 Healthcare Conference on November 15, 2023, to discuss the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes. A live webcast will be available for investors, and one-on-one meetings can be scheduled with vTv’s management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
News
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Rhea-AI Summary
vTv Therapeutics Inc. has appointed Thomas Strack, M.D. as Chief Medical Officer. Dr. Strack brings extensive drug development and clinical expertise to the company, with over 30 years of experience in academic clinical medicine and pharmaceutical drug development. He will play a prominent role in the execution of the planned Phase 3 program for cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
management
News
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
Rhea-AI Summary
vTv Therapeutics Inc. has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. Reneo has purchased all of its common stock granted to vTv under the Reneo License Agreement for approximately $4.4 million. The proceeds will provide financial support for vTv as they prepare for the launch of the cadisegliatin Phase 3 program in T1D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
Stock VTVT logo
vTv Therapeutics Inc

Nasdaq:VTVT

VTVT Rankings

#4596 Ranked by Market Cap
#4663 Ranked by Stock Gains
N/A Ranked by Dividends

VTVT Stock Data

59.67M
835.88k
54.68%
16.06%
1.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
High Point

About VTVT

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.